Plasma lipids affect dabigatran etexilate anticoagulation in rats with unbalanced diabetes mellitus
| Autor: | Alina Scridon, Adriana Vântu, Philippe Chevalier, Doina Gherţescu, Paul C. FişcĂ, Alina MĂrginean, Adina Huţanu, Marcel Perian, Razvan Constantin Serban, Dan Dobreanu |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
medicine.diagnostic_test medicine.drug_class Cholesterol business.industry Endocrinology Diabetes and Metabolism Anticoagulant Renal function 030204 cardiovascular system & hematology Thrombin time medicine.disease Affect (psychology) Dabigatran 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Endocrinology chemistry Internal medicine Diabetes mellitus medicine 030212 general & internal medicine business medicine.drug Lipoprotein |
| Zdroj: | Journal of Diabetes. 10:240-248 |
| ISSN: | 1753-0393 |
| DOI: | 10.1111/1753-0407.12580 |
| Popis: | Background Dabigatran etexilate (DE) appears to ensure similar efficacy for stroke prevention in patients with and without diabetes mellitus (DM). However, the benefit of reducing major bleeding was not seen in diabetics. Thus, we aimed to investigate the anticoagulant response to DE and the biological predictors of this response using an experimental DM model. Methods Six control rats (C), 8 DE-treated controls (CD), 5 diabetics (D), and 8 DE-treated diabetics (DD) were investigated. Plasma glucose (GLU), triglycerides, total cholesterol (CHOL), high- and low-density lipoprotein (LDL) cholesterol, and plasma creatinine were measured. Correlations were ascertained with the diluted thrombin time (dTT). Results When corrected for similar DE intake, dTT was significantly higher in DD compared to CD (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|